摘要
小分子酪氨酸激酶抑制剂(替尼类药物)作为新的靶向抗肿瘤药物,是近年来抗肿瘤药物研究的热点,此类药物已有多个上市,其为临床治疗肿瘤提供了更多的选择。吉非替尼作为此类药物的代表,在临床上应用广泛,效果良好。本文从这类药物中最具代表性的吉非替尼入手,对吉非替尼相关专利申请状况进行了分析,并重点对吉非替尼的专利技术发展路线进行了介绍,还对重要申请人的专利申请发展路线进行了梳理,在此基础上为国内研发机构和相关企业对于吉非替尼的后期开发、专利保护策略以及知识产权布局提供有益的参考和建议。
As a new kind of targeted anti-tumor drug, the small molecular tyrosine kinase inhibitors have become the focus of the research and development of anti-tumor drugs in recent years. There have been several such drugs in the market, which provide more choices for the clinical treatment of cancer. Gefitinib, as a representative of such drugs, has been widely used in clinical practice and has a significant effect. In this article, we analyzed the patent application status and introduced the patent technology roadmap of gefitinib and also conducted a carding of its main applicants to provide some useful reference and recommendations on the development, patent protection countermeasure and intellectual property strategy of gefitinib for the domestic pharmaceutical enterprises.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2015年第12期1326-1333,1348,共9页
Chinese Journal of New Drugs
关键词
吉非替尼
抗肿瘤药物
专利技术
专利分析
专利布局
gefitinib
anti-tumor drug
patent technology
patent analysis
patent portfolio
